Latest Lineagen Inc. Stories
SALT LAKE CITY, Jan. 15, 2013 /PRNewswire/ -- Lineagen, Inc. today announced publication of the results of a 9,000-person genetic study that demonstrates an approximately 100% increase in the detection rate of genetic markers now validated as being associated with autism spectrum disorders (ASDs). The study, one of the largest genetic validation studies in autism, was designed to confirm novel copy number genetic variants and novel next-generation sequence variants associated...
LOS ANGELES and SALT LAKE CITY, Dec. 3, 2012 /PRNewswire/ -- The Center for Autism and Related Disorders (CARD) and Lineagen, Inc. today announced the launch of a new clinical partnership to offer Lineagen's FirstStep(Dx)® genetic test to patients and their families. FirstStep(Dx) is a whole-genome genetic test customized with validated, novel proprietary genetic variants associated with ASDs. Under the terms of the partnership agreement, FirstStep(Dx), integrated with a pre-and...
We are advised by Lineagen, Inc. that journalists and other readers should disregard the news release, Lineagen Presents Data Showing Clinical Utilization of FirstStepDx®, a New Model of Genetic Service Delivery, at the 2012 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, issued March 29, 2012 over PR Newswire. Release was distributed prematurely. SOURCE Lineagen, Inc.
CHARLOTTE, N.C., March 29, 2012 /PRNewswire/ -- Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, today presented clinical utilization data for Lineagen's FirstStepDx. FirstStepDx is a comprehensive evaluation service that integrates highly advanced and comprehensive genetic testing for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD) with personalized pre- and...
SANTA CLARA, Calif. and SALT LAKE CITY, March 28, 2012 /PRNewswire/ -- Affymetrix, Inc. (NASDAQ: AFFX) and Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, today announced the companies have signed an agreement to incorporate Affymetrix' GeneChip® technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism...
SALT LAKE CITY, Dec. 14, 2011 /PRNewswire/ -- Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, and Fast Forward, LLC, a nonprofit subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the clinical development and validation of a blood-based assay for multiple sclerosis (MS). The goal of the program is to develop a test that can aid clinicians in diagnosing MS, distinguishing it from...
